Do analysts rate SBTX or SCYX?

SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 611.21%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend MENS or SCYX?

SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 611.21%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, MENS or SCYX?

Jyong Biotech has higher earnings, but lower revenue than SCYNEXIS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A SCYNEXIS $20.60M 2.24 -$8.61M -$2.09 N/A

Does the media prefer MENS or SCYX?

In the previous week, SCYNEXIS had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for SCYNEXIS and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.75 beat SCYNEXIS's score of 0.25 indicating that Jyong Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SCYX or LFCR?

In the previous week, SCYNEXIS had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for SCYNEXIS and 1 mentions for Lifecore Biomedical. SCYNEXIS's average media sentiment score of 0.25 beat Lifecore Biomedical's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NMRA or SCYX?

In the previous week, SCYNEXIS had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for SCYNEXIS and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat SCYNEXIS's score of 0.25 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

SCYNEXIS (SCYX) Competitors

$4.64 -0.22 (-4.53%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.71 +0.07 (+1.51%)

As of 06:36 AM Eastern

Compare

SCYX vs. SBTX, MENS, LFCR, NMRA, and NRXP

Should you buy SCYNEXIS stock or one of its competitors? SCYNEXIS's main competitors and comparable companies include Silverback Therapeutics (SBTX), Jyong Biotech (MENS), Lifecore Biomedical (LFCR), Neumora Therapeutics (NMRA), and NRx Pharmaceuticals (NRXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SCYNEXIS compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

SCYNEXIS has higher revenue and earnings than Silverback Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A

Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 611.21%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SCYNEXIS had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for Silverback Therapeutics. SCYNEXIS's average media sentiment score of 0.25 beat Silverback Therapeutics' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
SCYNEXIS	Neutral

Silverback Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Silverback Therapeutics' return on equity of -29.62% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
SCYNEXIS	-41.79%	-44.15%	-32.61%

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

SCYNEXIS beats Silverback Therapeutics on 9 of the 15 factors compared between the two stocks.

How does SCYNEXIS compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 611.21%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SCYNEXIS had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for SCYNEXIS and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.75 beat SCYNEXIS's score of 0.25 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jyong Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jyong Biotech has higher earnings, but lower revenue than SCYNEXIS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A

Jyong Biotech has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Jyong Biotech's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
SCYNEXIS	-41.79%	-44.15%	-32.61%

54.4% of SCYNEXIS shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jyong Biotech has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

SCYNEXIS beats Jyong Biotech on 7 of the 13 factors compared between the two stocks.

How does SCYNEXIS compare to Lifecore Biomedical?

SCYNEXIS (NASDAQ:SCYX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SCYNEXIS had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for SCYNEXIS and 1 mentions for Lifecore Biomedical. SCYNEXIS's average media sentiment score of 0.25 beat Lifecore Biomedical's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SCYNEXIS has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A
Lifecore Biomedical	$128.87M	1.29	-$40.50M	-$1.07	N/A

SCYNEXIS presently has a consensus price target of $33.00, indicating a potential upside of 611.21%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 47.73%. Given SCYNEXIS's stronger consensus rating and higher possible upside, research analysts clearly believe SCYNEXIS is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SCYNEXIS has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Lifecore Biomedical has a net margin of -29.93% compared to SCYNEXIS's net margin of -41.79%. Lifecore Biomedical's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Summary

SCYNEXIS beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 798.60%. SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 611.21%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Neumora Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SCYNEXIS has higher revenue and earnings than Neumora Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A

Neumora Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Neumora Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

In the previous week, SCYNEXIS had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for SCYNEXIS and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat SCYNEXIS's score of 0.25 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Neumora Therapeutics beats SCYNEXIS on 10 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to NRx Pharmaceuticals?

SCYNEXIS (NASDAQ:SCYX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

SCYNEXIS has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A
NRx Pharmaceuticals	$1.23M	111.24	-$28.62M	-$0.55	N/A

In the previous week, SCYNEXIS had 3 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for NRx Pharmaceuticals. SCYNEXIS's average media sentiment score of 0.25 beat NRx Pharmaceuticals' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Neutral
NRx Pharmaceuticals	Neutral

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SCYNEXIS currently has a consensus target price of $33.00, indicating a potential upside of 611.21%. NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 991.77%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

SCYNEXIS has a net margin of -41.79% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

SCYNEXIS has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

Summary

SCYNEXIS and NRx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCYX vs. The Competition

Export

Metric	SCYNEXIS	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$48.35M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-2.22	792.28	274.08	25.69
Price / Sales	2.24	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.51	10.59	10.47	6.32
Net Income	-$8.61M	$2.81B	$3.49B	$359.73M
7 Day Performance	4.27%	-0.11%	-0.67%	0.17%
1 Month Performance	-11.79%	-1.34%	-3.17%	-3.27%
1 Year Performance	-46.79%	2.86%	15.14%	5.58%

SCYNEXIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCYX SCYNEXIS	2.7866 of 5 stars	$4.64 -4.5%	$33.00 +611.2%	-45.8%	$48.35M	$20.60M	N/A	29
SBTX Silverback Therapeutics	N/A	$4.50 -5.5%	N/A	-54.2%	$162.26M	N/A	N/A	83	High Trading Volume
MENS Jyong Biotech	N/A	$2.12 +1.9%	N/A	-96.5%	$161.18M	N/A	N/A	27	Positive News Gap Up
LFCR Lifecore Biomedical	1.1156 of 5 stars	$4.14 -2.6%	$6.50 +57.0%	-44.3%	$156.71M	$128.87M	N/A	382	Positive News
NMRA Neumora Therapeutics	2.4487 of 5 stars	$0.83 -16.8%	$6.57 +690.5%	-61.7%	$156.20M	N/A	N/A	63	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCYX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SCYNEXIS (SCYX) Competitors

SCYX vs. SBTX, MENS, LFCR, NMRA, and NRXP

How does SCYNEXIS compare to Silverback Therapeutics?

Summary

How does SCYNEXIS compare to Jyong Biotech?

Summary

How does SCYNEXIS compare to Lifecore Biomedical?

Summary

How does SCYNEXIS compare to Neumora Therapeutics?

Summary

How does SCYNEXIS compare to NRx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SCYNEXIS (SCYX) Competitors

SCYX vs. SBTX, MENS, LFCR, NMRA, and NRXP

How does SCYNEXIS compare to Silverback Therapeutics?

Which has stronger earnings & valuation, SBTX or SCYX?

Which has more volatility & risk, SBTX or SCYX?

Do analysts rate SBTX or SCYX?

Does the media prefer SBTX or SCYX?

Is SBTX or SCYX more profitable?

Do insiders & institutionals hold more shares of SBTX or SCYX?

Summary

How does SCYNEXIS compare to Jyong Biotech?

Do analysts recommend MENS or SCYX?

Does the media prefer MENS or SCYX?

Which has better earnings & valuation, MENS or SCYX?

Is MENS or SCYX more profitable?

Do insiders & institutionals believe in MENS or SCYX?

Which has more volatility & risk, MENS or SCYX?

Summary

How does SCYNEXIS compare to Lifecore Biomedical?

Do institutionals & insiders hold more shares of SCYX or LFCR?

Does the media refer more to SCYX or LFCR?

Which has stronger earnings & valuation, SCYX or LFCR?

Do analysts recommend SCYX or LFCR?

Which has more volatility and risk, SCYX or LFCR?

Is SCYX or LFCR more profitable?

Summary

How does SCYNEXIS compare to Neumora Therapeutics?

Do analysts prefer NMRA or SCYX?

Which has preferable valuation & earnings, NMRA or SCYX?

Is NMRA or SCYX more profitable?

Which has more risk and volatility, NMRA or SCYX?

Does the media prefer NMRA or SCYX?

Do institutionals & insiders have more ownership in NMRA or SCYX?

Summary

How does SCYNEXIS compare to NRx Pharmaceuticals?

Which has preferable valuation and earnings, SCYX or NRXP?

Does the media prefer SCYX or NRXP?

Do insiders & institutionals hold more shares of SCYX or NRXP?

Do analysts prefer SCYX or NRXP?

Is SCYX or NRXP more profitable?

Which has more volatility and risk, SCYX or NRXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools